ShopBack Celebrates Two Years in HK - Over HK$100 Million in Cashback Rewarded to Customers

Partnering with Standard Chartered Bank to Launch Extra Cashback for the Year-End Shopping Season

Link to download photos:
https://drive.google.com/drive/folders/1A6tZarLYtfCniEUKUEOHtpoTWNq_Dn6o?usp=sharing

HONG KONG, Nov. 4, 2024 /PRNewswire/ -- As the year-end shopping season approaches, savvy shoppers looking to maximize their savings, earn more rewards and win big prizes cannot miss out on the latest offers from ShopBack. Asia and Hong Kong's largest online Cashback platform is rolling out two spectacular promotions. Simply clicking through ShopBack to make purchases at participating merchants, shoppers can earn Cashback from ShopBack on every transaction, anytime and anywhere at ease. In addition, new customers will have an opportunity to enter the grand lucky draw for prizes including up to HK$100,000 in spending credits and nearly HK$300,000 worth of surprise gifts.On top of this, ShopBack is introducing another exciting offer through its first-ever partnership with Standard Chartered Bank. Simply spend with designated Standard Chartered credit cards through ShopBack at selected merchants and customers can earn an extra HK$1,800 or more in Cashback offered by Standard Chartered. With these promotions, customers can enjoy triple the rewards, echoing ShopBack's motto: If it is not a steal, it is not a ShopBack Deal!

ShopBack Shopping Festival Lucky Draw – Win HK$100,000 in Spending Credits 
The peak shopping season is just around the corner – from 11.11, Thanksgiving, Black Friday, Cyber Monday, 12.12 sale events to Christmas all on the horizon! In addition to enjoying Cashback for every online purchase made through ShopBack, new customers who spend at least HK$100 in November will be entered into the ShopBack Shopping Festival Lucky Draw. Whether the purchase is for travel, dining, health products, groceries, fashion or electronics, customers will have a chance to win prizes, including HK$100,000 in spending credits, HK$30,000 in travel vouchers, an iPhone 16 Pro Max, round-trip tickets to Hokkaido, and more! Terms and conditions apply. For further details, please visit: https://app.shopback.com/sbhk-11-11-campaign

Extra Cashback with Designated Standard Chartered Credit Cards 
For the first time, ShopBack is partnering with Standard Chartered Bank to bring customers even more rewards. By shopping via ShopBack and spending with designated Standard Chartered credit cards at merchants like iHerb, Taobao, Watsons, Net-A-Porter, Mr Porter, and Harrods, customers can earn an extra HK$1,800 or more in Cashback. This offer allows customers to enjoy double rewards, as they will also be eligible for entry into the ShopBack Shopping Festival Lucky Draw alongside the Cashback offered by the Standard Chartered credit cards. Terms and conditions apply. For more details, please visit: https://app.shopback.com/sbhk-scb-partnership-campaign

ShopBack's Two-Year Entry in Hong Kong: Over HK$100 Million in Cashback Rewarded 
Mr. Arthur Wan, General Manager of ShopBack for Hong Kong and Taiwan, stated, "Since ShopBack's launch in Hong Kong over two years ago, we have been committed to helping our customers earn more Cashback while shopping. To date, we have rewarded customers with over HK$100 million in Cashback. For the first time, we are proud to be partnering with our inaugural banking partner, Standard Chartered Bank, to offer even more exciting rewards to our customers – creating a win-win for all parties."

Hong Kong's online shopping market continues to show immense potential. In August alone, the city's e-commerce sales reached HK$2.3 billion, with ShopBack transactions accounting for nearly 10% of that total. Wan added, "Online shopping has become an integral part of life for Hong Kong people. Thanks to our reliable platform, attractive Cashback offers and easy-to-use interface, the number of ShopBack members in Hong Kong has grown rapidly to over 600,000, while our partner merchants have increased to over 600, catering to a wide range of shopping needs."

Founded in 2014, ShopBack operates in 12 countries and regions worldwide. Last year, the Group marked a key milestone by expanding into Germany, signaling its entry into the European market. Globally, ShopBack serves over 45 million customers, rewarding more than US$475 million in total Cashback. With over 500,000 transactions processed daily, ShopBack drives over US$4 billion in annual sales for more than 20,000 online and in-store partners.

Getting started with ShopBack is simple and free. After registering, customers can shop just like they always do by accessing their merchants through ShopBack website or app. Once the purchase is completed and confirmed by the merchant, the Cashback is credited to the customer's ShopBack account. This Cashback can then be withdrawn via FPS to the customer's bank account for use as real cash.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

ShopBack Celebrates Two Years in HK - Over HK$100 Million in Cashback Rewarded to Customers

ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across 
North America, Asia, Europe and the Middle East

NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) randomized controlled trial (RCT). This landmark study represents a significant milestone in the field of interventional cardiology, evaluating the clinical and economic benefits of the CathWorks FFRangio^® System in diagnosing and treating coronary artery disease (CAD), offering potentially groundbreaking evidence that could redefine the standard of care.

The ALL-RISE Study included over 1,924 patients across 59 sites in North America, Asia, Europe and the Middle East. Participants presenting with coronary stenoses of intermediate significance and requiring physiology assessment were randomized to receive either FFRangio-guided treatment or invasive pressure wire-guided treatment. Notably, this was the first-ever randomized controlled trial in the United States to assess clinical outcomes using an angiography-based tool for physiologic lesion assessment.

In a joint statement, the ALL-RISE Study Chair, Dr. Ajay J. Kirtane (NewYork-Presbyterian/Columbia University Irving Medical Center) and Principal Investigators, Dr. William Fearon (Stanford University) and Dr. Allen Jeremias (St. Francis Hospital & Heart Center), stated, "On behalf of the study executive committee, we would like to congratulate and thank all the global investigators, study coordinators and patients who collectively enabled this incredible accomplishment. The high level of engagement and record speed of enrollment parallel the growing adoption of FFRangio globally. We look forward to sharing the results of this landmark study after clinical follow-up is completed."    

CathWorks Sr. Director of Clinical Affairs, Alex Froimovich M.D., added, "The completion of ALL-RISE enrollment marks a significant milestone for our company and team's mission to transform how cardiovascular disease is diagnosed and treated. We believe this study, adding to FFRangio's growing body of clinical evidence, has the potential to significantly advance the field of coronary physiology and close the gap between its current adoption and the appropriate use guidelines recommendations. FFRangio has already demonstrated higher diagnostic accuracy over all other angio-based technologies, highlighting the fact that not all angio-based technologies are created equal, and therefore technology-specific clinical data are needed."

Cardiovascular disease (CVD) remains the leading cause of death in the United States. According to the American Heart Association's (AHA) 2024 Heart Disease and Stroke Statistics Update, CVD accounted for 931,578 deaths in the U.S. in 2021, and close to 18 million deaths globally. Coronary artery disease (CAD) is the single largest contributor, responsible for over 40% of CV deaths. CathWorks believes the results from the ALL-RISE study will build on what the company refers to as a new era in physiology, underscoring FFRangio as the new standard of care with the potential to drive better patient outcomes while delivering tangible economic and resource utilization benefits to healthcare systems.

ABOUT CATHWORKS

CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio^® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on  LinkedIn. 

Investors:
Mike Feher
mike.feher@cath.works

Media:
Sarita Monico
sarita.monico@cath.works

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial